Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04423029
Title A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

cervical cancer

prostate cancer

Advanced Solid Tumor

hepatocellular carcinoma

breast cancer

kidney cancer

stomach cancer

renal cell carcinoma

endometrial cancer

lung non-small cell carcinoma

lung small cell carcinoma

ovarian cancer

Merkel cell carcinoma

melanoma

transitional cell carcinoma

skin squamous cell carcinoma

head and neck squamous cell carcinoma

triple-receptor negative breast cancer

esophageal cancer

Therapies

DF6002

DF6002 + Nivolumab

Age Groups: adult | senior
Covered Countries USA | FRA | ESP


No variant requirements are available.